Loading...
research article
Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis
2014
No therapy for non-alcoholic steatohepatitis (NASH) has been approved so far. Roux-en-y gastric bypass (RYGB) is emerging as a therapeutic option, although its effect on NASH and related hepatic molecular pathways is unclear from human studies. We studied the effect of RYGB on pre-existent NASH and hepatic mitochondrial dysfunction-a key player in NASH pathogenesis-in a novel diet-induced mouse model nicely mimicking human disease.
Type
research article
Web of Science ID
WOS:000350800100023
PubMed ID
24917551
Authors
Verbeek, Jef
•
Lannoo, Matthias
•
•
•
Spincemaille, Pieter
•
Vander Elst, Ingrid
•
Windmolders, Petra
•
Thevissen, Karin
•
Cammue, Bruno P A
•
van Pelt, Jos
Publication date
2014
Published in
Volume
64
Issue
4
Start page
673
End page
83
Peer reviewed
NON-REVIEWED
EPFL units
Available on Infoscience
April 14, 2015
Use this identifier to reference this record